Hello,
My name is Simon Akam and I am a contributing editor at the European edition of Newsweek magazine.
Hi Simon.
You probably need to post your email, I suggest you do it like this:
simon[AT]whatever[DOT]com
You raise several interesting points.
1. Most vapers who manage to succesfully switch away from smoking aren't doing it with small devices, since in ecigs battery size is everything. Unless the technology changes, the minimum usable battery capacity is 650mAh, as in the smallest of the eGo type devices. Such a device will work for some but not all smokers, especially when used with a very high strength nicotine refill (as the transfer efficiency is poor with low-profile devices). This is why the refill strengths go up to 45mg (4.5%) for these smaller devices; users of modern open-system gear can successfully use 3mg strength as the efficiency is so much better (mechmods and high-power boxmods with RBAs).
You can probably work out how much better open systems are, if they are successful with 3mg and 6mg strength, than these closed system proprietary (and all low-profile devices) are when they need up to 45mg refills to work.
Smokers who start out with small devices often need something bigger and more efficient to make vaping work. So they either fail and revert to smoking, or are lucky and come across info that leads them to better gear. Mini ecigs (aka cigalikes) are OK for social smokers and light smokers, but the average smoker is probably at around 12 to 15 cigs a day and minis etc generally do not work for them. It requires a product that will deliver at least 30 - 50 mg of nicotine per day in the vapour, and plenty of vapour volume. More vaped nicotine is needed because smoked nicotine is potentiated by multiple additional compounds, such as all the other active alkaloids in tobacco and the MAOIs, and therefore 'works better'. Smoking is not all about the nicotine, no matter what you read.
2. Consumers prefer a wide choice because vaping is successful due to the choice - of the thousands of possible combinations of equopment and refill, most do not work for any given individual. If choice is restricted, success is restricted in proportion.
Closed systems like the Vype are designed to lock-in consumers, but vaping works by offering unlimited choice. It's like tea: if you could only buy green tea, loose, of a brand you didn't like the taste of - then instead of 50 million tea drinkers in the UK (or whatever) you'd have 25,000. An instant reduction of 99.5%. Tea is popular because of the choice - what you like doesn't suit me at all.
3. Medical licensing is a red herring. An ecig, as we know it, cannot be licensed. The MHRA have made it very clear that no current ecig can receive a pharmaceutical license no matter how much work is put into quality control or any other factor. What they require is a metered dose device, with a shut-off after a set number of puffs, that delivers a consistent dose no matter what user technique is employed. A consumer product cannot be turned into a medical product by a bit of tweaking and some more quality: it works in a different way. You cannot have a metered dose of coffee and auto shut-off by using a kettle and cup - but you can have it by using a fully-packaged machine. Costs are far higher and consumers will not like the result in any case. Part of medical licensing requirements are that the product
must not be pleasant to use - you should probably think about this a little.
The MHRA will certainly license a product that may look like an ecig and may be sold as an ecig. It won't be an ecig though, it will be a repackaged asthma inhaler of some kind, and will appeal to consumers like an expensive and not very efficient enema does.
All these things are starter products for smokers who are not aware of the huge online communities and therefore what works far better and where to get it. They either fail or move up. The regulatory process is designed to remove that upgrade path.
Chris Price
Please quote any of this. Also see my resource site at
E-Cigarette Politics for a more detailed explanation of the politics, the economic implications, and the role of the public health industry in protecting cigarette sales in order to benefit the pharmaceutical industry.
Twitter: @rolygate